The World Anti-Doping Agency and Astellas Pharma have signed a global agreement to partner on the prevention of misuse and abuse of medicines for doping in sports.
Doping in sports depends on the misuse and abuse of commercially available medicines, as well as compounds in development that are not as popular or easily detected.
Under this agreement, Astellas will identify compounds solely developed by it or its affiliates with the potential for sport-related doping abuse and will cooperate in sharing relevant information to help WADA in the organisation's development of detection methods for these compounds.
Furthermore, Astellas will cooperate with WADA to reduce the risk of misuse of compounds with doping potential during clinical trials to avoid opportunities for abuse.
WADA president Sir Craig Reedie said: "WADA is encouraged to be partnering with Astellas on the prevention of misuse and abuse of medicines for doping in sports.
"It's a win-win arrangement. Essentially, Astellas will inform WADA during compound development if there is potential for future abuse in sport, and, the Agency commits to inform Astellas should it uncover evidence of black market supply involving their compounds.
"This partnership acknowledges that the impacts of doping extend well beyond elite athletes to include society on the whole."
Astellas chief strategy officer Kenji Yasukawa said: "Astellas is committed to ensuring the safe and effective use of its therapies in appropriate settings, and we are proud to be the first Japanese-based company to partner with WADA in its efforts to prevent the inappropriate use of medical products through doping.
"Enhancing performance in sports through doping is considered a serious public health issue by the sport movement and public authorities worldwide. It is critical that pharmaceutical companies play a role in helping to address this important public health concern."
Astellas claimed that its activities are aligned with recent guidance published by WADA and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to help pharmaceutical and biotechnology companies bolster their role in the fight against sport-related doping.